^
BIOMARKER:

MSI-H/dMMR

i
Other names: MSI-H, Microsatellite instability - high, dMMR




Show legend

Include preclinical:
Colorectal Cancer
Endometrial Cancer
Colon Cancer
Gastroesophageal Junction Adenocarcinoma
Gastric Cancer
Solid Tumor
Rectal Cancer
Small Intestinal Carcinoma
Prostate Cancer
Gastrointestinal Cancer
Esophageal Adenocarcinoma
Biliary Tract Cancer
Testicular Cancer
Breast Cancer
Ovarian Cancer
Cervical Cancer
Urothelial Cancer
Hepatocellular Cancer
Pancreatic Adenocarcinoma
Esophageal Cancer
Glioblastoma
Osteosarcoma
Uterine Cancer
Gallbladder Cancer
Anal Carcinoma
Genito-urinary Cancer
Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma
Peritoneal Cancer
Colorectal Adenocarcinoma
Small Cell Lung Cancer
Non Small Cell Lung Cancer
Adrenal Cortex Carcinoma
Renal Cell Carcinoma
Endometrial Adenocarcinoma
Neuroendocrine Tumor
Melanoma
Gastric Adenocarcinoma
Chordoma
Ewing Sarcoma
Soft Tissue Sarcoma
Thyroid Gland Papillary Carcinoma
Penile Cancer
Vulvar Cancer
Maxillary Sinus Carcinoma
Fallopian Tube Cancer
Cholangiocarcinoma
Head and Neck Cancer
Germ Cell Tumors
Glioma
pembrolizumab
PD-L1 inhibitor
PD1 inhibitor
Immunotherapy
CAPOX
FOLFOX
pembrolizumab + ipilimumab
EGFR inhibitor + VEGFR inhibitor
PD1 inhibitor + Immunotherapy
FLOT
nivolumab
dostarlimab-gxly
durvalumab + tremelimumab
cemiplimab-rwlc
pembrolizumab + lenvatinib
nivolumab + ipilimumab
tislelizumab
envafolimab
sintilimab
avelumab
atezolizumab
durvalumab
pucotenlimab
ipilimumab biosimilar (CS1002) + CS1003
QL1604
pembrolizumab + bevacizumab
bevacizumab + atezolizumab + rucaparib
tremelimumab
STI-A1014
pembrolizumab + enzalutamide capsule
fruquintinib
bevacizumab
AZD1775
bevacizumab + toripalimab-tpzi
paclitaxel + docetaxel + etoposide IV
TACH101
pembrolizumab + BBI608
nivolumab + pimitespib
pembrolizumab
nivolumab + cabozantinib tablet
camrelizumab + SHR7390
fruquintinib + geptanolimab
toripalimab-tpzi
BMS-986016
JNJ-63723283
nivolumab + bevacizumab
anlotinib + sintilimab
XmAb717
regorafenib
camrelizumab
ipilimumab
INCB86550
pembrolizumab + nivolumab + ipilimumab
retifanlimab-dlwr
serplulimab
capecitabine
talazoparib
cisplatin + gemcitabine + gimeracil/oteracil/tegafur
abemaciclib
5-fluorouracil + oxaliplatin
olaparib
M7824
niraparib
rucaparib